Drug intelligence / Profile preview

192 IgG-saporin

Development stage
Preclinical
Lead developer
Advanced Targeting Systems
Modality
Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intrathecal, Intravenous
01

Overview

192 IgG-saporin is a **targeted immunotoxin** composed of the mouse monoclonal antibody **192 IgG**, which specifically binds to the **p75 neurotrophin receptor (NGFR, low-affinity nerve growth factor receptor)**, conjugated to **saporin**, a ribosome-inactivating protein. The antibody component confers selectivity for cholinergic neurons—primarily in the basal forebrain—while the saporin payload induces cell death by irreversibly inactivating ribosomes. This immunotoxin is widely used in neuroscience research to selectively ablate cholinergic neurons in animal models, especially to create models of disorders featuring cholinergic hypofunction, such as **Alzheimer’s disease**, via intracerebroventricular (i.c.v.) injection. The drug’s action leads to memory deficits and other behavioral changes, primarily through the loss of cholinergic input to the hippocampus and cortex, with secondary effects on microglia and non-cholinergic systems[1][2][3][4][5][6].

Brand names
192 IgG-saporin
Other names
192 IgG-saporin192-IgG-SAPIg-saporin192 IgG-SAPanti-p75-SAPanti-p-75-SAPanti-p 75-SAPanti-neuronal immunotoxin
02

Targets

TNFRSF (TNF receptor superfamily)28S ribosomal RNA (28S rRNA)

Beyond the preview

Go deeper on 192 IgG-saporin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 192 IgG-saporin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call